SAN FRANCISCO—ORBIT II, a prospective, multicenter, single-arm clinical trial, was designed to evaluate the safety and efficacy of the Diamondback 360° Orbital Atherectomy System to treat de novo severely calcified coronary lesions. Results presented March 9 by Jeffrey W. Chambers, MD, at the American College of Cardiology (ACC) scientific session showed that the trial met its primary safety and efficacy endpoints: 30-day major adverse cardiac events (cardiac death, MI, target lesion revascularization) and procedural success.
About the presenter
Chambers is director of research and cardiac catheterization lab director at Metropolitan Heart and Vascular Institute at Mercy Hospital in Minneapolis. ORBIT II was funded by Cardiovascular Systems in Minneapolis.